Next-Generation Strategies for Brain Drug Delivery- Valetudo Medtech
Learn More
Accelerating digital transformation processes within the built environment sector to meet critical sustainability goals
Spinout
90 •
Challenge
Biopharma companies struggle to deliver RNA, antibodies and small molecules safely to target tissues, with more than 98 % blocked by the blood – brain barrier. Existing systems fail due to toxicity and scalability. Valetudo Medtech addresses this challenge with a patented red blood cell platform, enabling precise and scalable braintargeted delivery.
Solution
Valetudo Medtech’ s patented red blood cell-based platform transforms the body’ s own blood into a safe, targeted delivery system for RNA, antibodies and small molecules. Its technology uniquely crosses the blood – brain barrier, reduces toxicity and is scalable to good manufacturing practice( GMP) standards, enabling pharma to overcome delivery barriers, rescue stalled assets and accelerate clinical success in high-value markets such as brain cancer and neurodegenerative diseases.
The spinout generates revenue through a B2B model, licensing its patented delivery platform to pharmaceutical and biotech companies. In parallel, it offers contract manufacturing services for GMP-grade red blood cellbased drug delivery.
Target customers / end-users
• primary customers: biopharma / biotech developing RNA, antibodies, small molecules
• focus: overcoming delivery barriers in oncology and neurology
• first target: mid-sized biotechs in brain cancer and neurodegeneration.
Progress
• patented delivery platform with > 80 % loading efficiency
• > AU $ 500k secured in grants
• multiple pharma NDAs signed, and strong investor / partner validation targeting the multibillion brain therapeutics market.
Lab validated
TRL 4
Multidisciplinary team
Healthy Living
This UNSW spinout is developing a patented platform that uses red blood cells to deliver RNA, drugs and antibodies directly to diseased tissues. Its technology uniquely crosses the blood – brain barrier, unlocking new treatments for brain cancers and neurodegenerative diseases.